| Abstract [eng] |
Introduction. Iron deficiency anemia is the most common type of anemia diagnosed in children. Intravenous iron is one of treatment options. In pediatric population, data on the use of low molecular weight dextran remains limited, there are no data of iron isomaltoside. The aim of this study is to assess and compare safety and efficacy of iron isomaltoside and low molecular weight dextran. Subjects and methods. Retrospective data were collected from pediatric patients who received intravenous iron at Vilnius University Hospital Santaros Clinics between 01 January 2021 and 31 December 2023. Demographics, early and late hematologic response, adverse effects were analyzed. Early hematologic response was evaluated by analyzing pre-treatment and post-treatment hemoglobin content of reticulocytes and reticulocytes (%), late response – by changes in hemoglobin, red blood cells count, mean corpuscular volume, ferritin and transferrin saturation. All data were analyzed using statistical tests. Results. The study included 72 patients with median age of 13,5 years (IQR 6-15), with two of them below 12 months. Both low molecular weight dextran and iron isomaltoside showed significant results in early and late hematological response, p<0,05. Four patients (5,6%) experienced mild adverse effects. The hematologic response and adverse effects rate did not differ between the two IV products. Conclusion. Both low molecular weight dextran and iron isomaltoside demonstrated safety and efficacy in children with iron deficiency anemia treatment. |
